We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

81 hedge funds and large institutions have $314M invested in Kindred Biosciences, Inc. in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 17

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

63% more call options, than puts

Call options by funds: $252K | Put options by funds: $155K

39% more capital invested

Capital invested by funds: $226M → $314M (+$88M)

11% more funds holding

Funds holding: 7381 (+8)

Holders
81
Holders Change
+8
Holders Change %
+10.96%
% of All Funds
1.85%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
36
Reduced
17
Closed
12
Calls
$252K
Puts
$155K
Net Calls
+$97K
Net Calls Change
+$449K
Name Holding Trade Value Shares
Change
Change in
Stake
PWAM
1
Park West Asset Management
California
$83.7M
AI
2
Ariel Investments
Illinois
$30.4M -$576K -42,600 -2%
Morgan Stanley
3
Morgan Stanley
New York
$30.3M +$101K +7,438 +0.3%
BlackRock
4
BlackRock
New York
$25.5M +$6.82M +504,246 +38%
Vanguard Group
5
Vanguard Group
Pennsylvania
$19.7M +$1.08M +80,023 +6%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$18.8M +$51.9K +3,839 +0.3%
Renaissance Technologies
7
Renaissance Technologies
New York
$14.7M +$1.42M +105,100 +11%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$13.3M -$338K -25,000 -3%
GIM
9
Granahan Investment Management
Massachusetts
$8.82M +$4.24M +313,377 +98%
GAI
10
General American Investors
New York
$6.4M -$1.84M -136,061 -23%
State Street
11
State Street
Massachusetts
$5.61M +$324K +23,921 +6%
Northern Trust
12
Northern Trust
Illinois
$5.32M +$1.25M +92,709 +32%
PVAM
13
Pacific View Asset Management
California
$4.78M -$2.73M -202,135 -37%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.67M +$713K +52,685 +19%
New York State Common Retirement Fund
15
New York State Common Retirement Fund
New York
$4.38M +$435K +32,132 +11%
Allianz Asset Management
16
Allianz Asset Management
Germany
$3.5M +$3.4M +250,967 New
Invesco
17
Invesco
Georgia
$2.75M +$2.67M +197,222 New
Wells Fargo
18
Wells Fargo
California
$2.34M -$2.09M -154,294 -48%
SAM
19
Silverback Asset Management
North Carolina
$2.07M +$2.01M +148,400 New
EI
20
EAM Investors
California
$1.96M +$1.04M +76,743 +120%
AFS
21
Amtrust Financial Services
New York
$1.81M -$1.05M -77,541 -37%
EGI
22
EAM Global Investors
California
$1.35M +$1.31M +96,808 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.27M +$241K +17,798 +24%
Two Sigma Investments
24
Two Sigma Investments
New York
$1.21M +$388K +28,708 +49%
Squarepoint
25
Squarepoint
New York
$1.21M +$642K +47,445 +121%

KIN Hedge Fund Activity: Q3 2018 in Review

81 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q3 2018, worth a combined $314M — up 39% from $226M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new KIN positions and 12 closed out — a net gain of 8 holders — while 36 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $6.82M. The largest seller was Pacific View Asset Management, cutting an estimated $2.73M.

  • 81 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q3 2018, up from 73 in Q2 2018.
  • Funds reported $314M of Kindred Biosciences, Inc. stock for Q3 2018, up 39% quarter-over-quarter.
  • 20 funds opened new Kindred Biosciences, Inc. positions in Q3 2018 and 12 closed out, a net change of +8 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q3 2018 was BlackRock, an estimated $6.82M added.
  • The largest Kindred Biosciences, Inc. seller in Q3 2018 was Pacific View Asset Management, an estimated $2.73M sold.

Based on aggregated 13F filings for Q3 2018.